Lung cancer immune cell trial halted after just 2 patients
NCT ID NCT06235242
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early trial tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back along with an immune-boosting drug called teraplizumab. The goal was to see if this combination is safe and tolerable for people with advanced non-small cell lung cancer. Only 2 patients were enrolled before the study was terminated, so we have very limited information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
autologous tumor-infiltrating lymphocytes (GT201) plus teraplizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced non-small cell lung cancer using a patient's own immune cells.
What could go wrong
This was a very small, early safety trial with only 2 participants and has already been terminated, so results are limited and may not apply to others. Risks include severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
-
Shanghai GoBroad Cancer Hospital
Shanghai, Shanghai Municipality, 200120, China